MT-7716, a potent NOP receptor agonist, preferentially reduces ethanol seeking and reinforcement in post-dependent

Giordano de Guglielmo1,2, Rémi Martin-Fardon1, Koji Teshima3

  • 1Molecular and Cellular Neuroscience Department, The Scripps Research Institute, La Jolla, CA, USA.

Addiction Biology
|June 17, 2014
PubMed

Insights

The nociceptin (N/OFQ) system, targeted by novel agonist MT-7716, shows promise for treating alcohol abuse. MT-7716 reduced alcohol seeking in dependent rats, suggesting potential for relapse prevention.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Addiction Research

Background:

  • The nociceptin (N/OFQ) system is implicated in alcohol abuse.
  • Targeting the N/OFQ system may offer therapeutic benefits for alcoholism.

Purpose of the Study:

  • To investigate the efficacy of a novel non-peptide NOP agonist, MT-7716, in reducing alcohol self-administration and relapse.
  • To evaluate MT-7716's effects in both non-dependent and post-dependent rat models.

Main Methods:

  • Rats were trained to self-administer ethanol and made dependent.
  • MT-7716 (0.3 and 1 mg/kg) was administered orally to assess effects on alcohol intake and stress-induced relapse.
  • Testing occurred 2 weeks after dependence induction and 1-3 weeks post-withdrawal.

Main Results:

  • MT-7716 significantly reduced alcohol self-administration in post-dependent rats.
  • MT-7716 decreased stress-induced reinstatement of alcohol seeking in post-dependent rats.
  • The drug was ineffective in non-dependent animals, with greater effect seen 3 weeks post-dependence.

Conclusions:

  • The NOP receptor represents a viable therapeutic target for alcohol use disorder.
  • Non-peptide NOP agonists like MT-7716 are promising candidates for alcohol abuse treatment and relapse prevention.
  • N/OFQ system dysregulation contributes to alcohol seeking and reinforcement behaviors.